260 related articles for article (PubMed ID: 37426807)
21. Trastuzumab deruxtecan for HER2+ advanced breast cancer.
Lee J; Park YH
Future Oncol; 2022 Jan; 18(1):7-19. PubMed ID: 34823373
[TBL] [Abstract][Full Text] [Related]
22. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
Shitara K; Bang YJ; Iwasa S; Sugimoto N; Ryu MH; Sakai D; Chung HC; Kawakami H; Yabusaki H; Lee J; Saito K; Kawaguchi Y; Kamio T; Kojima A; Sugihara M; Yamaguchi K;
N Engl J Med; 2020 Jun; 382(25):2419-2430. PubMed ID: 32469182
[TBL] [Abstract][Full Text] [Related]
23. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
Cortés J; Kim SB; Chung WP; Im SA; Park YH; Hegg R; Kim MH; Tseng LM; Petry V; Chung CF; Iwata H; Hamilton E; Curigliano G; Xu B; Huang CS; Kim JH; Chiu JWY; Pedrini JL; Lee C; Liu Y; Cathcart J; Bako E; Verma S; Hurvitz SA;
N Engl J Med; 2022 Mar; 386(12):1143-1154. PubMed ID: 35320644
[TBL] [Abstract][Full Text] [Related]
24. The efficacy and safety of anti-PD-1/PD-L1 in treatment of glioma: a single-arm meta-analysis.
Zeng YF; Wei XY; Guo QH; Chen SY; Deng S; Liu ZZ; Gong ZC; Zeng WJ
Front Immunol; 2023; 14():1168244. PubMed ID: 37122727
[TBL] [Abstract][Full Text] [Related]
25. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer.
Rugo HS; Bianchini G; Cortes J; Henning JW; Untch M
ESMO Open; 2022 Aug; 7(4):100553. PubMed ID: 35964548
[TBL] [Abstract][Full Text] [Related]
26. Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis.
Yuan Y; Liu X; Cai Y; Li W
Syst Rev; 2022 Dec; 11(1):264. PubMed ID: 36496473
[TBL] [Abstract][Full Text] [Related]
27. Modified xiaoyao san combined with chemotherapy for breast cancer: A systematic review and meta-analysis of randomized controlled trials.
Pan J; Fu S; Zhou Q; Lin D; Chen Q
Front Oncol; 2023; 13():1050337. PubMed ID: 37035186
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Apatinib for the Treatment of Advanced or Recurrent Cervical Cancer: A Single-Arm Meta-Analysis Among Chinese Patients.
Huang D; He Q; Zhai L; Shen J; Jing F; Chen H; Zhu X; Zhou J
Front Pharmacol; 2022; 13():843905. PubMed ID: 36034824
[No Abstract] [Full Text] [Related]
29. Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials.
Xu ZQ; Zhang Y; Li N; Liu PJ; Gao L; Gao X; Tie XJ
BMJ Open; 2017 Mar; 7(3):e013053. PubMed ID: 28289045
[TBL] [Abstract][Full Text] [Related]
30. Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer.
Nie T; Blair HA
Target Oncol; 2023 May; 18(3):463-470. PubMed ID: 37129796
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of apatinib monotherapy for patients with advanced breast cancer: a systematic review and meta-analysis.
Huang X; Hu X; Yi T
Front Oncol; 2022; 12():940171. PubMed ID: 35978823
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of HER2-targeted therapy in patients with colorectal cancer: What should we expect from a meta-analysis?
Wang M; Su J; Lu J; Yang Z; Wang J; Zhong Y; Zeng T; Shen K; Lin S
Clin Res Hepatol Gastroenterol; 2023 Feb; 47(2):102078. PubMed ID: 36627051
[TBL] [Abstract][Full Text] [Related]
33. Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis.
Wilson FR; Coombes ME; Wylie Q; Yurchenko M; Brezden-Masley C; Hutton B; Skidmore B; Cameron C
Syst Rev; 2017 Oct; 6(1):196. PubMed ID: 29017563
[TBL] [Abstract][Full Text] [Related]
34. Pyrotinib versus lapatinib therapy for HER2 positive metastatic breast cancer patients after first-line treatment failure: A meta-analysis and systematic review.
Yuan Y; Liu X; Cai Y; Li W
PLoS One; 2023; 18(1):e0279775. PubMed ID: 36602979
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of pembrolizumab on cervical cancer: A systematic review and single-arm meta-analysis.
Qi L; Li N; Lin A; Wang X; Cong J
Front Oncol; 2022; 12():910486. PubMed ID: 36033480
[TBL] [Abstract][Full Text] [Related]
36. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
Modi S; Park H; Murthy RK; Iwata H; Tamura K; Tsurutani J; Moreno-Aspitia A; Doi T; Sagara Y; Redfern C; Krop IE; Lee C; Fujisaki Y; Sugihara M; Zhang L; Shahidi J; Takahashi S
J Clin Oncol; 2020 Jun; 38(17):1887-1896. PubMed ID: 32058843
[TBL] [Abstract][Full Text] [Related]
37. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of
Ma J; Hu X; Li L; Rao Z; Zhang C
Front Oncol; 2022; 12():993182. PubMed ID: 36505778
[TBL] [Abstract][Full Text] [Related]
39. Chinese herbal medicine combined with oxaliplatin-based chemotherapy for advanced gastric cancer: A systematic review and meta-analysis of contributions of specific medicinal materials to tumor response.
Tan Y; Wang H; Xu B; Zhang X; Zhu G; Ge Y; Lu T; Gao R; Li J
Front Pharmacol; 2022; 13():977708. PubMed ID: 36091754
[No Abstract] [Full Text] [Related]
40. Continuation of trastuzumab beyond progression in HER2-positive advanced esophagogastric cancer: a meta-analysis.
Ter Veer E; van den Ende T; Creemers A; de Waal L; van Oijen MGH; van Laarhoven HWM
Acta Oncol; 2018 Dec; 57(12):1599-1604. PubMed ID: 30264641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
